Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Total Current Liabilities (2016 - 2025)

Avanos Medical's Total Current Liabilities history spans 10 years, with the latest figure at $234.6 million for Q4 2023.

  • For Q4 2023, Total Current Liabilities rose 22.83% year-over-year to $234.6 million; the TTM value through Dec 2023 reached $234.6 million, up 22.83%, while the annual FY2023 figure was $234.6 million, 22.83% up from the prior year.
  • Total Current Liabilities for Q4 2023 was $234.6 million at Avanos Medical, up from $170.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $234.6 million in Q4 2023 and bottomed at $129.2 million in Q3 2021.
  • The 5-year median for Total Current Liabilities is $170.7 million (2023), against an average of $176.0 million.
  • The largest annual shift saw Total Current Liabilities dropped 27.98% in 2021 before it soared 37.21% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $212.5 million in 2019, then decreased by 21.74% to $166.3 million in 2020, then decreased by 16.3% to $139.2 million in 2021, then soared by 37.21% to $191.0 million in 2022, then rose by 22.83% to $234.6 million in 2023.
  • Per Business Quant, the three most recent readings for AVNS's Total Current Liabilities are $234.6 million (Q4 2023), $170.7 million (Q3 2023), and $160.5 million (Q2 2023).